A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically or cytologically confirmed Stage IIIB or Stage IV non-squamous non-small cell lung cancer (NSCLC) * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * For patients who received prior adjuvant chemotherapy or chemoradiotherapy: a treatment-free interval of at least 12 months since last chemotherapy or chemoradiotherapy cycle * Adequate tissue for central immunohistochemical (IHC) assay of Met receptor, and epidermal growth factor receptor (EGFR) testing if EGFR status is unknown * Radiographic evidence of disease Exclusion Criteria: * Prior systemic treatment for Stage IIIB or IV non-squamous NSCLC * Evidence of mixed NSCLC with a predominance of the squamous cell type * Prior exposure to experimental treatment targeting either the hepatocyte growth factor (HGF) or Met pathway * Patients with tumors confirmed to have EGFR-activating mutations who are suitable for anti-EGFR therapy (e.g. gefitinib or erlotinib), as determined by the investigator, unless that treatment is unavailable or refused by the patient * Known central nervous system (CNS) disease, other than stable, treated brain metastases * History of another malignancy in the previous 3 years, except for history of in situ cancer that was treated surgically with curative intent, localized prostate cancer that has been treated surgically with curative intent, or basal or squamous cell skin cancer * Uncontrolled diabetes * Pregnant or lactating women * Impaired bone marrow, liver or renal function (as defined by protocol) * Significant history of cardiovascular disease * Positive for HIV infection